"Xin Maide" completes nearly 300 million yuan Series B financing

robot
Abstract generation in progress

Mars Finance News, recently, the domestic drug delivery company “Xin Maide” announced the completion of nearly 300 million yuan in Series B funding.
This round of financing was led by Suzhou Industrial Park Yuanhe Yuandian Venture Capital Management Co., Ltd., with existing shareholders Hongyuan Capital and Dahua Venture Capital Management Co., Ltd. participating as co-investors, along with Jin Yu Mao Wu, Changshu Economic Development Holding Fund, Changshu Guofa Venture Capital, and other institutions.
After this financing is completed, Xin Maide will focus on pulmonary drug delivery, nasal drug delivery, and other advanced drug delivery directions, continuously promoting the construction of delivery technology platforms for innovative drugs, and further strengthening and expanding its comprehensive capabilities in original research and development, precision engineering, industrialization, and global cooperation.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin